JMPer Cable

Latest Posts

• Self-described “analytics evangelist” Craig DePorter of Omya discusses why analytics enablement means learning more with less

  Advocating for analytics at Omya Craig DePorter of Omya

  Meg_Hermes

  JMPer Cable |

  Dec 19, 2023 1:38 PM

  3566 views | 0 replies
  

• Safety Results IIIb: Significant Adverse Events by AE Risk Report in JMP® Clinical

  In our recent paper, CDISC Enables Efficient Streamlining of Clinical Trial Safety Evaluation^1,2, we followed FDA NDA (New Drug Application) or CR (Clinical Reviews) templates to show how drug safety can be evaluated. My previous blogs demonstrated how to capture SAEs using Adverse Events Narrative³, and Discontinuations Due⁴ to AEs and TEAE⁵ with Adverse Events Distribution. There is a final step...

  Wenjun_Bao_JMP

  JMPer Cable |

  Nov 16, 2023 8:00 AM

  1417 views | 0 replies
  

• Safety Results IIIa: TEAE by Adverse Events Distribution in JMP® Clinical

  In our recent paper, CDISC Enables Efficient Streamlining of Clinical Trial Safety Evaluation^1,2, we followed FDA NDA (New Drug Application) or CR (Clinical Reviews) templates to show how drug safety can be evaluated. My previous blogs demonstrated how to evaluate SAEs by Adverse Events Narrative³ and Discontinuations Due to AEs⁴ by Adverse Events Distribution. We'll now look at the third step for...

  Wenjun_Bao_JMP

  JMPer Cable |

  Nov 14, 2023 8:00 AM

  5302 views | 0 replies
  

• Safety Results II: Discontinuations due to AEs evaluated by AE Distribution in JMP® Clinical

  In our recent paper, CDISC Enables Efficient Streamlining of Clinical Trial Safety Evaluation^1,2, we followed FDA NDA (New Drug Application) or CR (Clinical Reviews) templates to show how drug safety can be evaluated. My blog, Safety Result I, explained how to use the Adverse Events Narrative to summarize the individual information³ for those subjects that had a SAE in CR for Latuda⁴. The below fi...

  Wenjun_Bao_JMP

  JMPer Cable |

  Nov 9, 2023 9:00 AM

  1009 views | 0 replies
  

• Safety Results I: Using the Adverse Events Narrative in JMP® Clinical to describe deaths and SAEs

  In our recent paper, CDISC Enables Efficient Streamlining of Clinical Trial Safety Evaluation^1,2, we followed FDA NDA (New Drug Application) or CR (Clinical Reviews) templates to show how drug safety is evaluated by reviewers at the U.S. FDA. The typical template, shown below, is from an NDA for Mydayis³. The major content in the safety review can be found in the Safety Results section. Assessin...

  Wenjun_Bao_JMP

  JMPer Cable |

  Nov 7, 2023 1:30 PM

  1732 views | 0 replies
  

• Summary of clinical trials using JMP® Clinical

  Before we can understand clinical trial data in detail, we need to understand the protocol or trial design to get a big picture of the clinical trial data. This data can be described in three ways: trial, event, and treatment emergent adverse events (TEAE) summaries, as explained in our recent paper CDISC Enables Efficient Streamlining of Clinical Trial Safety Evaluation^1,2.
  
  Trial summaries can be...

  Wenjun_Bao_JMP

  JMPer Cable |

  Nov 7, 2023 1:30 PM

  1308 views | 0 replies
  

• New Medical Queries: FMQ and AFMQ Implemented in JMP® Clinical

  The FDA announced the release of the FDA Medical Query (FMQ) and Algorithmic FDA Medical Queries (AFMQ) at the Duke Margolis-FDA Workshop: Advancing Premarket Safety Analytics¹ on Sept 14, 2022. The description of FMQ and AFMQ can be found in this FDA presentation: Advancing Premarket Safety Analytics². Traditional medical queries (Standard Medical Queries (SMQ))³ focused primarily on MedDRA prefe...

  Wenjun_Bao_JMP

  JMPer Cable |

  Nov 7, 2023 1:29 PM

  4482 views | 0 replies
  

• 'CDISC Enables Efficient Streamlining of Clinical Trial Safety Evaluation' published in JSCDM

  Creating a library of peer-reviewed articles focused on the implementation of CDISC standards.

  Wenjun_Bao_JMP

  JMPer Cable |

  Sep 26, 2023 10:27 PM

  1114 views | 0 replies
  

• Identifying and Understanding the Impact of Collinearity

  That pesky collinearity! What is it? How do I detect it? How is it related to the VIF shown in JMP reports? How do I interpret VIF?Ultimitaley, how do I build models that accurately account for collinearity?   Correlation? Yes! Graph Builder Shows Negative Relationship Between Y and X2 when X1 and X2 are Both in Models

  gail_massari

  JMPer Cable |

  Sep 8, 2023 1:00 PM

  3169 views | 0 replies
  

• How to perform gene expression data analysis in JMP® Pro 17: Part 4 - Modelization

  See modelization of gene expression data using JMP Pro 17.

  Valerie_Nedbal

  JMPer Cable |

  Aug 21, 2023 7:20 AM

  1329 views | 0 replies
  

• How to perform gene expression data analysis in JMP® Pro 17: Part 3 – Compare Groups

  See how to compare groups for differentiated expression of genes in JMP Pro 17.

  Valerie_Nedbal

  JMPer Cable |

  Aug 14, 2023 7:30 AM

  1800 views | 1 replies
  

• How do I begin connecting JMP® to my database?

  JMP can connect to a number of database management systems (Oracle, SQL Server, etc.) that provide Unicode 3.5 Unicode Standard drivers. Users, new and experienced, often have data sources that require ODBC to connect JMP to a relational database to import data for analysis. Sometimes users looking to connect with their databases don't know where to begin and want to know how to obtain their datab...

  Dahlia_Watkins

  JMPer Cable |

  Aug 11, 2023 8:37 AM

  5829 views | 0 replies
  

• How to perform gene expression data analysis in JMP® Pro 17: Part 2 - Control and Quality

  The "Gene Expression Data Analysis in JMP Pro" blog series continues, focused on control and quality.

  Valerie_Nedbal

  JMPer Cable |

  Aug 8, 2023 7:30 AM

  1432 views | 0 replies
  

• Demystifying the Suppress Formula Eval data table option

  Learn when JMP suppresses formula evaluation and how you can access options to turn off suppression.

  Duane_Hayes

  JMPer Cable |

  Jul 12, 2023 10:47 AM

  2209 views | 0 replies
  

• Manage Limits for JMP 17

  Wouldn’t it be great if the manage spec limits utility allowed you to alter more than just the specification limits?  Well you’re in luck!   

  tonya_mauldin

  JMPer Cable |

  May 25, 2023 12:00 PM

  2638 views | 0 replies
  

• New Features in Process Screening for JMP 17

  JMP 17 brings about some key changes to the Process Screening platform. Menu changes lead to better organization and allow users to find options easier. New commands such as Filter Where, Show Charts as Selected, Chart Options, the Process Screening column property, and Platform Preferences provide key enhancements and improve the usability of the Process Screening platform.

  tonya_mauldin

  JMPer Cable |

  May 18, 2023 7:00 AM

  1774 views | 0 replies
  

• CUSUM New Features in JMP 17

  JMP 17 introduces many CUSUM (cumulative sum) control chart platform updates. New options include Save Sigma, Save Limits, Get Limits, and Platform Preferences. Also, test failures are now in the summary table.

  tonya_mauldin

  JMPer Cable |

  May 4, 2023 11:00 AM

  1683 views | 0 replies
  

• EWMA New Features in JMP 17

  JMP 17 introduces many new updates to the EWMA (exponentially weighted moving average) platform. New options include K Sigma, Save Sigma, Connect Thru Missing, Save Limits, Get Limits, and Platform Preferences. Also, information about the average and residuals chart is now in the summary table.

  tonya_mauldin

  JMPer Cable |

  Apr 27, 2023 7:00 AM

  1781 views | 0 replies
  

• Shapley Values: Explaining Individual Predicted Probabilities

  What if you need to pinpoint the main contributing factor to a prediction for a single person? Some modeling algorithms do not easily answer this. Some methods can. Enter Shapley Values.

  KristenBradford

  JMPer Cable |

  Apr 18, 2023 10:53 AM

  7468 views | 8 replies
  

• Distribution new features for JMP 17

  JMP 17 brings new features to the Distribution platform. 

  tonya_mauldin

  JMPer Cable |

  Apr 18, 2023 5:53 AM

  1940 views | 0 replies